Literature DB >> 20354890

Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.

Shiomi Yoshida1, Katsuhiro Suzuki, Tomotada Iwamoto, Kazunari Tsuyuguchi, Motohisa Tomita, Masaji Okada, Mitsunori Sakatani.   

Abstract

We compared rifabutin susceptibility and rpoB mutations in 98 multi-drug-resistant strains of Mycobacterium tuberculosis (MDR-TB) by DNA sequencing and with a line probe assay using the commercially available INNO-LiPA Rif. TB kit (the LiPA). Our results indicated that rifabutin continues to remain active against MDR-TB strains harboring certain genetic alterations and also that the LiPA might be useful in identifying MDR-TB strains susceptible to rifabutin.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354890     DOI： 10.1007/s10156-010-0057-5

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


  11 in total

1.  Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis.

Authors:  Huang-Yao Chen; Ming-Chih Yu; Wei-Lun Huang; Mei-Hua Wu; Yung-Lin Chang; Chien-Rai Che; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

Review 2.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

3.  Isoniazid and Rifampin-Resistance Mutations Associated With Resistance to Second-Line Drugs and With Sputum Culture Conversion.

Authors:  Eleanor S Click; Ekaterina V Kurbatova; Heather Alexander; Tracy L Dalton; Michael P Chen; James E Posey; Julia Ershova; J Peter Cegielski
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

4.  The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

Authors:  Michael G Whitfield; Robin M Warren; Vanessa Mathys; Lesley Scott; Elise De Vos; Wendy Stevens; Elizabeth M Streicher; Guido Groenen; Frederick A Sirgel; Annelies Van Rie
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

Review 5.  An appraisal of PCR-based technology in the detection of Mycobacterium tuberculosis.

Authors:  Sathish Sankar; Mageshbabu Ramamurthy; Balaji Nandagopal; Gopalan Sridharan
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

6.  Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.

Authors:  Zenda L Berrada; Shou-Yean Grace Lin; Timothy C Rodwell; Duylinh Nguyen; Gisela F Schecter; Lucy Pham; J Michael Janda; Wael Elmaraachli; Antonino Catanzaro; Edward Desmond
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-03       Impact factor: 2.803

7.  Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.

Authors:  W ElMaraachli; M Slater; Z L Berrada; S-Y G Lin; A Catanzaro; E Desmond; C Rodrigues; T C Victor; V Crudu; M T Gler; T C Rodwell
Journal:  Int J Tuberc Lung Dis       Date:  2015-10       Impact factor: 2.373

8.  Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa.

Authors:  Ivy Rukasha; Halima M Said; Shaheed V Omar; Hendrik Koornhof; Andries W Dreyer; Alfred Musekiwa; Harry Moultrie; Anwar A Hoosen; Gilla Kaplan; Dorothy Fallows; Nazir Ismail
Journal:  Front Microbiol       Date:  2016-12-05       Impact factor: 5.640

9.  Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Authors:  Neesha Rockwood; Maddalena Cerrone; Melissa Barber; Andrew M Hill; Anton L Pozniak
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

10.  The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.

Authors:  Frederick A Sirgel; Robin M Warren; Erik C Böttger; Marisa Klopper; Thomas C Victor; Paul D van Helden
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.